ribociclib,adalimumab,adavosertib
astrazeneca,abbvie,mirati,amgen
['maintain data', 'ada ', 'lung', ' ada ', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', '$mrtx', 'mirati', '$amgn']
bofa raised pt $mrtx $91 was $88 | esmo | modest cb200 data lower bar for mirati, or portend class challenges in 2l lung crc: mrtx continues to maintain data lead over competitor; some debate on lower os from ada/egfr combo arm vs ada alone mrtx 4q data key $amgn $xbi $ibb